Severity of illness models for respiratory syncytial virus-associated hospitalization.
暂无分享,去创建一个
[1] L. Wright,et al. Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV , 1998, Pediatrics.
[2] W. Dankner. Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis , 1997, Pediatrics.
[3] E. Wang,et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. , 1997, The Journal of pediatrics.
[4] L. Wright,et al. Respiratory syncytial virus immune globulin intravenous: Indications for use , 1997 .
[5] W. Gruber,et al. Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections , 1997 .
[6] A. Laupacis,et al. Clinical prediction rules. A review and suggested modifications of methodological standards. , 1997, JAMA.
[7] A. Monto,et al. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. , 1996, Journal of clinical epidemiology.
[8] E. Simões,et al. RESPIRATORY SYNCYTIAL VIRUS IMMUNOGLOBULIN AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS IN CHILDREN WITH CONGENITAL HEART DISEASE. • 662 , 1996, Pediatric Research.
[9] S. Ohmit,et al. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. , 1996, The Journal of pediatrics.
[10] R. Jacobs,et al. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. , 1996, Pediatrics.
[11] S. Lemeshow,et al. Modeling the Severity of Illness of ICU Patients: A Systems Update , 1995 .
[12] E. Wang,et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. , 1995, The Journal of pediatrics.
[13] S. Lemeshow,et al. Modeling the severity of illness of ICU patients. A systems update. , 1994, JAMA.
[14] Matthew Gelmini,et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double‐blind, randomized trial , 1994, Critical care medicine.
[15] U. Ruttimann,et al. Statistical approaches to development and validation of predictive instruments. , 1994, Critical care clinics.
[16] C. Hall,et al. Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .
[17] R. Turner,et al. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. , 1993, The Pediatric infectious disease journal.
[18] W. Knaus,et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.
[19] D. W. Smith,et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. , 1991, The New England journal of medicine.
[20] S. Heidemann,et al. Does prematurity alter the course of respiratory syncytial virus infection? , 1990, Critical care medicine.
[21] C. Hall,et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. , 1990, The Journal of pediatrics.
[22] U. Ruttimann,et al. Pediatric risk of mortality (PRISM) score. , 1988, Critical care medicine.
[23] K. Gutierrez,et al. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. , 1988, Pediatrics.
[24] P. Getson,et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease , 1987, The Pediatric infectious disease journal.
[25] C B Hall,et al. Respiratory syncytial viral infection in children with compromised immune function. , 1986, The New England journal of medicine.
[26] R. Cornall,et al. Ribavirin aerosol for acute bronchiolitis. , 1986, Archives of disease in childhood.
[27] C. Hall,et al. Ribavirin Treatment of Respiratory Syncytial Viral Infection in Infants With Underlying Cardiopulmonary Disease , 1985 .
[28] V. Knight,et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. , 1983, Pediatrics.
[29] E. Walsh,et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. , 1983, The New England journal of medicine.
[30] C. Hall,et al. Respiratory syncytial viral infection in infants with congenital heart disease. , 1982, The New England journal of medicine.
[31] R. Douglas,et al. Nosocomial respiratory syncytial virus infections. , 1975, The New England journal of medicine.
[32] R. Chanock,et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.